Skip to NavigationSkip to content

News

0
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints...
0
Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated...
0
Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in the US and...
0
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the treatment...

Features

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores the history of...